共 50 条
- [42] Clinical efficacy of the gonadotropin-releasing hormone antagonist, ganirelix, in Korean women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer with recombinant follicle-stimulating hormone JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2005, 31 (03) : 227 - 235
- [43] Prediction of ovarian reserve based on day-3 serum follicle stimulating hormone concentrations during the pituitary suppression cycle using a gonadotropin releasing hormone agonist in patients undergoing in vitro fertilization-embryo transfer GYNECOLOGICAL ENDOCRINOLOGY, 2004, 18 (06) : 335 - 340
- [46] A randomized, assessor-blind, multicentre study to investigate the efficacy and efficiency of a starting dose of 100IU or 200IU of recombinant follicle stimulating hormone (Puregon®) in women undergoing controlled ovarian hyperstimulation for in vitro fertilization-embryo transfer treatment. FERTILITY AND STERILITY, 2003, 80 : S185 - S185
- [47] A study to determine the efficacy of controlled ovarian hyperstimulation regimen using a gonadotropin releasing hormone agonist versus antagonist in women of advanced reproductive age with varying degrees of oocyte reserve on outcome following in vitro fertilization-embryo transfer CLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY, 2013, 40 (02): : 191 - 192
- [48] Triggering ovulation with leuprolide acetate (LA) instead of human chorionic gonadotropin (hCG) after the use of ganirelix for in vitro fertilization-embryo transfer (IVF-ET) does not compromise cycle outcome and may prevent ovarian hyperstimulation syndrome FERTILITY AND STERILITY, 2001, 76 (03) : S93 - S93